Preclinical investigations

BioIVT has acquired XenoTech, a provider of products and services for preclinical testing that specialises in ADME, DMPK and DDI testing of potential drug candidates.  Through the acquisition, BioIVT aims to expand the portfolio of research models and services that are available to its clients to support their R&D function.   “XenoTech has a well-established and excellent reputation […]

Effective preclinical assessment of drug safety and efficacy is essential to help reduce the risk of drug-induced toxicity and late-stage drug attrition. Current preclinical tests for safety depend on in vivo testing in higher-order species to achieve translational accuracy; however, animal models are expensive and do not adequately recapitulate human physiology due to species differences. […]